Key Takeaways:
Incyte Corp. (Nasdaq: INCY) received U.S. Food and Drug Administration approval for Jakafi XR, a once-daily, extended-release version of its blockbuster drug ruxolitinib, for treating three distinct blood and graft-versus-host diseases.
“The approval of Jakafi XR reinforces Incyte’s leadership in hematology and our focus on meeting the evolving needs of patients with myeloproliferative neoplasms (MPNs) and GVHD,” Bill Meury, Chief Executive Officer of Incyte, said in a statement. “Jakafi XR offers appropriate patients and physicians a once-daily option, expanding choice without changing the well-established role of Jakafi in clinical practice.”
The new formulation is approved for adults with intermediate- or high-risk myelofibrosis (MF), adults with polycythemia vera (PV) who don't respond to or tolerate hydroxyurea, and for adults and children 12 and older with specific forms of graft-versus-host disease (GVHD). The approval was based on a study showing a 55 mg once-daily Jakafi XR tablet is bioequivalent to a 25 mg immediate-release tablet taken twice daily, providing a more convenient dosing regimen.
The approval strengthens Incyte’s multi-billion dollar Jakafi franchise ahead of its 2028 patent expiration. While the company's stock has gained 60 percent over the last year on 21 percent year-over-year revenue growth, analysts have noted the high revenue concentration in Jakafi as a primary risk. The introduction of an extended-release version could help defend its market share against future generic competition.
Jakafi XR offers a simplified treatment schedule for patients managing complex, chronic diseases. Myelofibrosis and polycythemia vera are rare, chronic blood cancers known as myeloproliferative neoplasms that disrupt the normal production of blood cells. Graft-versus-host disease is a serious complication that can occur after a stem cell transplant.
“Patients living with chronic conditions like MPNs and GVHD often struggle with managing complex treatment regimens,” said Dr. Naveen Pemmaraju, Professor of Leukemia at The University of Texas MD Anderson Cancer Center, which led several clinical trials for the drug. “With the approval of Jakafi XR, appropriate patients now have the choice of a single daily tablet.”
Incyte's management has guided for 2026 net sales of approximately $4.8 billion, with Jakafi continuing to represent the majority of that total. The stock currently trades at a price-to-earnings ratio of about 13x, a discount to its historical premium, reflecting investor concerns about the upcoming patent cliff.
The approval of Jakafi XR is a key part of Incyte's strategy to extend the drug's life cycle and solidify its market leadership in hematology. The new formulation provides a more convenient option for patients, which could improve adherence and outcomes. Investors will be watching closely to see how the launch of Jakafi XR and other potential new products in 2026 and 2027 impact the company's revenue growth and market valuation.
This article is for informational purposes only and does not constitute investment advice.
